
Early-stage B2B venture capital firm backed by experienced enterprise operators who invest alongside it

Texas- and California-focused venture firm backing early-stage information technology companies

Silver Creek Ventures has, across its current and former general partners, managed five institutionally funded venture capital funds and invested in more than 90 portfolio companies, concentrating on early-stage information technology businesses located mainly in California and Texas. General partner Michael Segrest has focused his investing on security, networking and services, having worked with more than 90 startup companies since 1991 and served on more than 35 portfolio company boards. Alongside his investing and board work, he was chief operating officer of Nimbix, a company offering high-performance computing in the cloud, from 2018 until it was bought by ATOS in 2021. Before joining Silver Creek Ventures, he was a principal at a merchant banking firm specialising in the communications industries, and holds undergraduate and graduate degrees from the University of Texas at Austin.
Summary written by TrustList from the business's own published information, Sep 2026.
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Silver Creek Ventures.
Similar listings buyers compare against this one.

Early-stage B2B venture capital firm backed by experienced enterprise operators who invest alongside it

Member-based investor group funding early-stage companies through monthly review and a chapter roadshow

Startup accelerator and early-stage investor running intensive batches for new technology founders

Venture capital firm partnering with founders from first idea through to public listing

Decentralised bandwidth network on which developers build and users run censorship-resistant VPN applications

Investment and advisory firm helping blockchain startups grow into established crypto projects

Venture capital firm backing underrepresented founders building climate and social impact technology

Life sciences investor financing biotech companies developing new therapies in Europe and the United States
Everything here links back to the same verified catalogue. Pick your next stop.